EDITOR,-Anderson and Vullo's hypothesis (Gut 1994; 35: 1487-9 ) is based on the contention that hypolactasia is causatively associated with riboflavin deficiency (consequent upon low milk intake), which has evolutionarily produced a survival advantage against human Plasmodium spp infection. Available evidence (quoted by the authors) indicates, however, that such a deficiency exerts only a very mild influence on the metabolism of the malarial parasite.
The overwhelming consensus of current opinion is that the hypolactasia phenotype represents the normal state for Homo sapiens' (and virtually all other mammals) , and that persistence of the enzyme into adult life in certain groups before 'artificial' mass population movements (for example, northern Europeans to the USA and Australia) resulted from a significant survival advantage; by involving malaria as the major 'driving force', Anderson and Vullo are thus interpreting the scenario in 'reverse' fashion. it never caused the widespread acute mortality associated with human P falciparum infection -which probably originated in Africa also comparatively recently. The approximate parallel outlined in the hypothesis between the geographical areas incorporating the hypolactasia phenotype and those in which major haemoglobinopathies (which clearly possess a selective advantage against P falciparum infection) are comparatively common, is of interest.4 5But even here the degree of protection is only partial; riboflavin deficiency has probably exerted a comparatively minimal, and certainly a lesser, effect in terms of selective Darwinian pressure.
Therefore, although this hypothesis seems superficially attractive, I have grave doubts that it explains the human lactase polymorphism more satisfactorily than several of the previous theories.' G Reply EDITOR,-We thank Dr G C Cook for his interest in our hypothesis and would like to reply to some of his points. Dr Cook says that 'available evidence (quoted by the authors) indicates, however, that such a deficiency exerts only a very mild influence on the metabolism of the malarial parasite'. We believe that the crucial point is not whether the influence of flavin deficiency on the parasite metabolism is 'mild' or 'very mild', but whether its effect is sufficient to prevent excessive multiplication of the parasite as it has been shown in vivo and quoted in our paper, so protecting the host from death.
Dr Cook also says that our hypothesis implies that 'persistence of the enzyme into adult life only developed very much later in areas where Plasmodium spp was not a major environmental hazard affecting survival'. It is possible that we have not made it clear that the basis of our hypothesis is that the 'persistent' phenotype was the 'wild type' existent initially, and therefore we did not envisage that it 'developed' later but that it continued to predominate in those areas.
Even if, as it seems today, there is no evidence that the Hamite tribe (who possess the 'persistent' phenotype) are more prone to malaria than the Bantus, this does not necessarily show that our hypothesis is wrong, because they could be protected by other factors, known we have recently studied the bile duct stone dissolving capacity of multicomponent solvents in humans.3 In these mixtures, DMSO was present both in solvent 1 (aqueous glycine-NaOH buffer solution of EDTA, sodium deoxycholate and 30% DMSO) and in solvent 2 (DMSO/MTBE 70/30). Solvent mixtures were infused continuously and alternately for 16-24 hours through a nasobiliary catheter placed into the common bile duct over the stone(s). In 20 of 22 patients with pigment or mixed biliary duct stone(s), or both, which were too large to be removed after endoscopic sphincterotomy, a stone free state (nine of 22) or good disintegration of stones (11 of We do agree with Takacs and Montet that the multilayered composition of bile duct stones make the combined use of DMSO, MTBE, or EDTA, or all three, a logical choice. Indeed, the use of DMSO for dissolving bile duct stones in humans has been described before but reports have been anecdotal.1-3 We are still very reluctant to infuse potentially toxic agents into human bile ducts. In contrast with topical dissolution of gall bladder stones, where the gall bladder provides a reservoir enabling actual extraction of the solvent after infusion, topical dissolution of ductal stones lacks the opportunity to recover the solvent from the patient. This increases the risk of toxic side effects. We and others4 have found MTBE to produce much more local (haemorraghic duodenitis) and systemic side effects (somnolentia,
